Mode
Text Size
Log in / Sign up

Bacterial pneumonia

Part of Pneumonia

4 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials for bacterial pneumonia

21 trials tracked for bacterial pneumonia: 11 in phase 3 or 4 and 3 with published results. The most-cited published study has 236 citations.

21Trials tracked
11Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 4 1 Phase 3 10 Phase 2 7 Other / NA 3
  1. Phase 3 Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13) Completed · 236 cited
  2. Phase 3 Imipenem/Relebactam/Cilastatin Versus Piperacillin/Tazobactam for Treatment of Participants With Bacterial Pneumonia (MK-7655A-014) Completed · 233 cited
  3. Phase 3 Inhaled Amikacin Solution BAY41-6551 as Adjunctive Therapy in the Treatment of Gram-Negative Pneumonia Completed · 131 cited
  4. Phase 4 Pharmacodynamic of Ceftaroline and Levofloxacin Against Pathogens Associated With Community Acquired Bacterial Pneumonia Completed
  5. Phase 3 Efficacy and Safety of Nemonoxacin vs Levofloxacin in Adult Patients With Community-Acquired Pneumonia Completed
  6. Phase 3 Omadacycline vs. Moxifloxacin for the Treatment of Community-Acquired Bacterial Pneumonia Completed
Show 15 more trials
  1. Phase 3 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed
  2. Phase 3 The Study of Unasyn-S 12g/Day for Community Acquired Pneumonia (CAP) Completed
  3. Phase 3 Comparative Study of Ceftaroline vs. Ceftriaxone in Adults With Community-Acquired Pneumonia Completed
  4. Phase 3 Comparison of Telavancin and Vancomycin for Hospital-acquired Pneumonia Due to Methicillin-resistant Staphylococcus Aureus Completed
  5. Phase 3 Comparative Study of Ceftaroline vs. Ceftriaxone in Adult Subjects With Community-Acquired Pneumonia Completed
  6. Phase 2 A Study Of Intravenous Sulopenem And Oral PF-03709270 In Community Acquired Pneumonia That Requires Hospitalization Completed
  7. Phase 2 An Effectiveness, Safety, and Microbiology Study of Doripenem in Patients With Nosocomial (Hospital-acquired) Pneumonia Completed
  8. Phase 2 A Single Ascending Dose Study in Adults (Stage 1) and Single Ascending Dose-Finding Study (Stage 2) in Elderly Subjects With ASP3772, A Pneumococcal Vaccine Completed
  9. Phase 2 A Safety and Tolerability Study of Doripenem in Patients With Abdominal Infections or Pneumonia Completed
  10. Phase 2 Study Evaluating the Pharmacokinetics (PK), Safety, and Tolerability of Tigecycline in Patients 8 to 11 Years of Age Completed
  11. Phase 2 Cx611-0204 SEPCELL Study Completed
  12. Phase 2 Aerosolized Amikacin and Fosfomycin in Mechanically Ventilated Patients With Gram-negative Pneumonia Completed
  13. N/A Vaccination Education Through Pharmacists and Senior Centers (VEPSC) Completed
  14. N/A Urease Breath Test for Rapid Characterization of Pneumonia Completed
  15. N/A PROcalcitonin Impact on Antibiotic Reduction, adverSe Events and AVoidable healthcarE Costs (ProSAVE): A RCT Completed

Showing the 21 most-cited and recently-updated of 21 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

What the trials found For clinicians

Bacterial pneumonia: what the trials found

Several agents have been evaluated for the treatment of bacterial pneumonia. Imipenem demonstrated a significant reduction in all-cause mortality at day 28 compared to the comparator (15.9% vs. 21.3%, p<0.001) and a significantly higher rate of favorable clinical response at early follow-up (61.0% vs. 55.8%, p<0.001) 3. Omadacycline showed high rates of clinical response, with approximately 87.7% to 95.9% of patients achieving an investigator's assessment of clinical response at various evaluation points 5.

Other established interventions include Ceftaroline [1, 8, 9], Omadacycline 2, ampicillin sodium/sulbactam sodium 7, Telavancin [10, 11], and Nemonoxacin 6. While Nemonoxacin was evaluated for clinical success and infection relapse, the results did not reach statistical significance (p=0.08 and p=0.154, respectively) 6.

Amikacin inhalation solution was evaluated in a trial where no statistically significant differences were found between treatment arms regarding survival, pneumonia-related death, or early clinical response 4.

Recent results — preliminary, needs further review

  • A study utilized the 13C-urea breath test to evaluate correlations with bacterial RNAseq counts, CURB-65 scores, and Pneumonia Severity Index in urease-positive pneumonia; however, no significant correlations were observed (p=0.00) 19.

For the clinician treating this condition

  • Imipenem is associated with significantly lower all-cause mortality at day 28 and higher early clinical response rates compared to the control group 3.
  • Omadicycline demonstrated high rates of investigator-assessed clinical response in patients with bacterial pneumonia 5.
  • Clinical evidence for several other agents, including Ceftaroline, Telavancin, and ampic1icin/sulbactam, is established but specific outcome metrics were not detailed in the provided data [1, 7, 8, 9, 10, 11].

AI synthesis of 7 cited trials, updated Jun 21, 2026. Informational only — not medical advice; trial data sourced from ClinicalTrials.gov. How we use AI.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.

Research across Pneumonia

Related studies from across the Pneumonia family.

Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF
Allergy & Immunology Sys. Review
Autoantibody positivity and false-negative cytology can mask invasive mucinous adenocarcinoma in patients with IPAF Lung cancer can mimic autoimmune lung disease in some patients
This case report describes a 78-year-old female with invasive mucinous adenocarcinoma and interstitial pneumonia with autoimmune features. T…
A new case shows how a rare lung cancer can look like an autoimmune disease, making it hard for doctors to tell them apart.
MRSA nares PCR does not cut vancomycin duration in ICU CAP
Infectious Disease RCT
MRSA nares PCR does not cut vancomycin duration in ICU CAP MRSA Testing Does Not Reduce Vancomycin Use in Pneumonia Patients
In a single-center randomized trial of 277 adult ICU patients with suspected community-acquired pneumonia, MRSA nares PCR testing did not si…
A trial of 277 ICU patients found that MRSA nasal swab testing did not reduce the amount of vancomycin used for pneumonia.
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds
Geriatrics & Aging Meta-analysis
Physical frailty tops risk factors for pneumonia after esophagectomy, meta-analysis finds Physical frailty and muscle loss increase pneumonia risk after surgery
This meta-analysis of 60 cohort studies in esophageal cancer patients undergoing esophagectomy identified physical frailty as the highest-ra…
Patients with esophageal cancer face a higher risk of pneumonia after surgery if they show signs of physical frailty or muscle loss.
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia
Infectious Disease RCT
Short-course ceftriaxone reduces hospital stay and adverse events in children with pneumonia Shorter antibiotic courses may help children with pneumonia stay home
This randomized controlled trial of 200 children aged 1 to 14 years found that short-course ceftriaxone (5 to 7 days) resulted in shorter ho…
A new trial shows that a shorter course of ceftriaxone can reduce hospital stays and side effects for children with pneumonia.
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients
Gastroenterology Sys. Review
Aerosolized liposomal amphotericin B provides strongest evidence for invasive pulmonary aspergillosis prophylaxis in high-risk patients Aerosolized Amphotericin B Shows Promise for Lung Fungal Infections
This mini review synthesizes clinical experience regarding aerosolized antifungal therapies for various pulmonary fungal infections. It conc…
Aerosolized liposomal amphotericin B shows promise for preventing specific lung fungal infections in high-risk and immunocompromised patient…
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods
Pediatrics Sys. Review
mNGS achieves 85.83% pathogen detection rate in children with severe pneumonia compared to 49.97% for conventional methods New Genetic Test Finds More Pneumonia Germs in Kids
This systematic review evaluates metagenomic next-generation sequencing (mNGS) for identifying pathogens in children with severe pneumonia. …
A new genetic test detects pneumonia-causing germs in kids more often than standard methods, which could lead to better treatment.
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis
Infectious Disease Meta-analysis
Inhaled antibiotics may improve lung function and microbiological eradication in cystic fibrosis and bronchiectasis Inhaled Antibiotics May Improve Lung Health in Chronic Lung Conditions
This meta-analysis evaluated the efficacy of inhaled antibiotics for patients with cystic fibrosis, non-cystic fibrosis bronchiectasis, and …
Inhaled antibiotics may improve lung function and clear infections for people with cystic fibrosis and other chronic lung conditions.
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children
Infectious Disease Sys. Review
Antibiotic exposure disrupts gut microbiota in 58% to 94% of critically ill children Antibiotics and gut health in critically ill children
This narrative review examines antibiotic exposure in critically ill children in the PICU, reporting that 58% to 94% receive antibiotics, wh…
Common antibiotics used in intensive care can disrupt a child's gut health, increasing the risk of serious infections like pneumonia.
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation
Pulmonology & Critical Care Meta-analysis
iNKT cell activators show promise in preclinical models for stroke-associated pneumonia immunomodulation New immune treatments show promise for stroke and pneumonia
This systematic review of 38 preclinical studies examines the immunopathology of stroke-associated pneumonia (SAP) and the role of immunomod…
Researchers identify how stroke triggers immune failure and find a promising new way to protect the lungs from pneumonia infections.
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation
Primary Care & Family Medicine Sys. Review
IL-6 overexpression linked to alveolar damage in severe pneumonia on ventilation IL-6 Levels Linked to Lung Damage in Severe Pneumonia
This narrative review synthesizes basic and clinical evidence on IL-6 in mechanically ventilated patients with severe pneumonia. It finds th…
High levels of a protein called IL-6 may be linked to increased lung damage and inflammation in patients with severe pneumonia.
Low-dose corticosteroids reduce 90-day mortality in adults with severe community-acquired pneumonia
Pulmonology & Critical Care Meta-analysis
Low-dose corticosteroids reduce 90-day mortality in adults with severe community-acquired pneumonia Low dose steroids may lower death rates in severe lung infections
This meta-analysis of 4,622 patients found that low-dose corticosteroids (≤400 mg hydrocortisone-equivalent daily) significantly reduced sho…
A review of clinical trials suggests that low-dose corticosteroids can reduce 90-day mortality for adults with severe lung infections like p…
Oral amoxicillin or amoxicillin-clavulanate is non-inferior to intravenous treatment for severe CAP in children
Pediatrics RCT
Oral amoxicillin or amoxicillin-clavulanate is non-inferior to intravenous treatment for severe CAP in children Trial shows oral antibiotics work for children with severe pneumonia
This randomized controlled trial of 1,101 children with severe community-acquired pneumonia in sub-Saharan Africa found that step-down oral …
A large trial in Africa found that switching children from IV to oral antibiotics for pneumonia is as safe and effective as staying on IV tr…